Lurasidone

Lurasidone is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions) in adults and children 13 years of age and older. It is also used to treat depression in adults and children 10 years of age and older with bipolar disorder (manic depressive disorder; a disease that causes episodes of depression, episodes of mania, and other abnormal moods). Lurasidone is also used along with lithium (Lithobid) or valproate (Depacon) to treat depression in adults with bipolar disorder. Lurasidone is in a class of medications called atypical antipsychotics. It works by changing the activity of certain natural substances in the brain.

Lurasidone comes as a tablet to take by mouth. It is usually taken with a meal (at least 350 calories) once a day. Take lurasidone at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take lurasidone exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Lurasidone controls schizophrenia and depression in people with bipolar disorder but it does not cure these conditions. It may take several weeks or longer before you feel the full benefit of lurasidone. Continue to take lurasidone even if you feel well. Do not stop taking lurasidone without talking to your doctor.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Before taking lurasidone,

• tell your doctor and pharmacist if you are allergic to lurasidone, any other medications, or any of the ingredients in lurasidone tablets. Ask your pharmacist for a list of the ingredients.

• tell your doctor if you are taking carbamazepine (Carbatrol, Epitol, Tegretol); clarithromycin (Biaxin, in Prevpac); ketoconazole; mibefradil; phenytoin (Dilantin, Phenytek); rifampin (Rifadin, Rimactane, in Rifamate, in Rifater); ritonavir (Norvir); St. John's wort; or voriconazole (Vfend). Your doctor will probably tell you not to take lurasidone if you are taking either of these medications.

• tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, and nutritional supplements you are taking or plan to take. Be sure to mention any of the following: antidepressants; antihistamines; atazanavir (Reyataz); bosentan (Tracleer); diltiazem (Cardizem, Cartia, Taztia, Tiazac, others); efavirenz (Sustiva, in Atripla); erythromycin (E.E.S., E-Mycin, Ery-Tab, others); etravirine (Intelence); fluconazole (Diflucan); indinavir (Crixivan); ipratropium (Atrovent, in Combivent, in Duoneb); itraconazole (Sporanox); medications to control anxiety, sedatives, sleeping pills, or tranquilizers; medications to control blood pressure; medications for glaucoma, inflammatory bowel disease, motion sickness, myasthenia gravis, Parkinson's disease, ulcers, or urinary problems; modafinil (Provigil); nafcillin; nefazodone; nelfinavir (Viracept); phenobarbital; pioglitazone (Actos, in Duetact, in Actoplus Met); rifabutin (Mycobutin); or verapamil (Calan, Verelan, others, in Tarka); Other medications may also interact with lurasidone, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.

• tell your doctor if you use or have ever used street drugs or have overused prescription medications and if you have or have ever had a stroke; a ministroke (TIA); chest pain, heart disease, or a heart attack; an irregular heartbeat; heart failure; Parkinson's disease (a disorder of the nervous system that causes difficulties with movement, muscle control, and balance); Alzheimer's disease (a brain disease that slowly destroys the memory and ability to think, learn, communicate and handle daily activities); seizures; dementia; breast cancer; trouble keeping your balance; any condition that makes it difficult for you to swallow; high or low blood pressure; high prolactin levels; a high level of fats (cholesterol and triglycerides) in your blood; a low number of white blood cells; kidney disease; liver disease; high blood sugar; or if you or anyone in your family has or has ever had diabetes. Tell your doctor if you have severe vomiting or diarrhea or signs of dehydration now, or if you develop these symptoms at any time during your treatment. Also tell your doctor if you have ever had to stop taking a medication for mental illness because of severe side effects.

• tell your doctor if you are pregnant, especially if you are in the last few months of your pregnancy, or if you plan to become pregnant or are breastfeeding. If you become pregnant while taking lurasidone, call your doctor. Lurasidone may cause problems in newborns following delivery if it is taken during the last months of pregnancy.

• if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking lurasidone.

• you should know that lurasidone may make you drowsy. Do not drive a car or operate hazardous machinery until you know how this medication affects you.

• you should know that you may experience hyperglycemia (increases in your blood sugar) while you are taking this medication, even if you do not already have diabetes. If you have schizophrenia, you are more likely to develop diabetes than people who do not have schizophrenia, and taking lurasidone or similar medications may increase this risk. Tell your doctor immediately if you have any of the following symptoms while you are taking lurasidone: extreme thirst, frequent urination, extreme hunger, blurred vision, or weakness. It is very important to call your doctor as soon as you have any of these symptoms, because high blood sugar can cause a serious condition called ketoacidosis. Ketoacidosis may become life-threatening if it is not treated at an early stage. Symptoms of ketoacidosis include dry mouth, nausea and vomiting, shortness of breath, breath that smells fruity, and decreased consciousness.

• you should know that lurasidone may cause dizziness, lightheadedness, and fainting when you get up too quickly from a lying position. This is more common when you first start taking lurasidone. To help avoid this problem, get out of bed slowly, resting your feet on the floor for a few minutes before standing up.

• you should know that lurasidone may make it harder for your body to cool down when it gets very hot. Tell your doctor if you plan to exercise or be exposed to extreme heat.

• you should know that lurasidone may cause an increase in weight. It is important to have your weight checked periodically while you are taking this medication.

Do not eat large amounts of grapefruit or drink grapefruit juice while taking this medication.

Take the missed dose with food (at least 350 calories) as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

• Lurasidone may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

  • dizziness, feeling unsteady, or having trouble keeping your balance

  • anxiety

  • weakness

  • tiredness

  • restlessness

  • uncontrollable shaking of a part of the body

  • slow movements or shuffling walk

  • nausea

  • vomiting

  • appetite changes

  • increased saliva

  • breast enlargement or discharge

  • late or missed menstrual period

  • decreased sexual ability

• Some side effects can be serious. If you experience any of these symptoms, or those listed in the IMPORTANT WARNINGS and SPECIAL PRECAUTIONS sections, call your doctor immediately:

  • seizures

  • swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles, or lower legs

  • hoarseness

  • difficulty swallowing or breathing

  • shortness of breath

  • abnormal heartbeat

  • sore throat, fever, cough, chills, and other signs of infection

  • fever, sweating, confusion, fast or irregular heartbeat, and severe muscle stiffness

  • unusual movements of your face or body that you cannot control

  • falling

• Lurasidone may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.

• If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom).

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Keep all appointments with your doctor and the laboratory. Your doctor may order certain lab tests to check your body's response to lurasidone.

Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug	Interaction
Moxifloxacin	Moxifloxacin The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Moxifloxacin.
Repaglinide	Repaglinide The therapeutic efficacy of Repaglinide can be decreased when used in combination with Lurasidone.
Insulin Glargine (rDNA origin) Injection	Insulin Glargine (rDNA origin) Injection The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Lurasidone.
Dolasetron	Dolasetron The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Dolasetron.
Anagrelide	Anagrelide The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Anagrelide.
Candesartan	Candesartan Lurasidone may decrease the antihypertensive activities of Candesartan.
Cilostazol	Cilostazol The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Lurasidone.
Diphenoxylate	Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lurasidone.
Erythromycin and Sulfisoxazole	Erythromycin and Sulfisoxazole The metabolism of Lurasidone can be decreased when combined with Erythromycin.
Guanfacine	Guanfacine The risk or severity of adverse effects can be increased when Lurasidone is combined with Guanfacine.
Methylergonovine	Methylergonovine The risk or severity of hypertension can be increased when Methylergometrine is combined with Lurasidone.
Miglitol	Miglitol The therapeutic efficacy of Miglitol can be decreased when used in combination with Lurasidone.
Naratriptan	Naratriptan The risk or severity of adverse effects can be increased when Naratriptan is combined with Lurasidone.
Olsalazine	Olsalazine The risk or severity of hypertension can be increased when Olsalazine is combined with Lurasidone.
Paregoric	Paregoric The risk or severity of adverse effects can be increased when Morphine is combined with Lurasidone.
Penbutolol	Penbutolol The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Acebutolol.
Pentazocine	Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Lurasidone.
Reserpine	Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Lurasidone.
Rizatriptan	Rizatriptan The risk or severity of adverse effects can be increased when Rizatriptan is combined with Lurasidone.
Sumatriptan	Sumatriptan The risk or severity of adverse effects can be increased when Sumatriptan is combined with Lurasidone.
Tacrolimus	Tacrolimus The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Lurasidone.
Tizanidine	Tizanidine The risk or severity of adverse effects can be increased when Tizanidine is combined with Lurasidone.
Zolmitriptan	Zolmitriptan The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Lurasidone.
Famotidine Injection	Famotidine Injection The risk or severity of QTc prolongation can be increased when Famotidine is combined with Lurasidone.
Fluconazole Injection	Fluconazole Injection The metabolism of Lurasidone can be decreased when combined with Fluconazole.
Foscarnet Injection	Foscarnet Injection The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Lurasidone.
Hydromorphone Injection	Hydromorphone Injection The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lurasidone.
Levofloxacin Injection	Levofloxacin Injection The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Levofloxacin.
Meperidine Injection	Meperidine Injection The risk or severity of adverse effects can be increased when Meperidine is combined with Lurasidone.
Metoclopramide Injection	Metoclopramide Injection The risk or severity of adverse effects can be increased when Metoclopramide is combined with Lurasidone.
Metronidazole Injection	Metronidazole Injection The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Lurasidone.
Morphine Injection	Morphine Injection The risk or severity of adverse effects can be increased when Morphine is combined with Lurasidone.
Altretamine	Altretamine The therapeutic efficacy of Lurasidone can be decreased when used in combination with Amphetamine.
Cyclosporine	Cyclosporine The metabolism of Lurasidone can be decreased when combined with Cyclosporine.
Ondansetron	Ondansetron The risk or severity of adverse effects can be increased when Ondansetron is combined with Lurasidone.
Granisetron	Granisetron The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Granisetron.
Torsemide	Torsemide Lurasidone may decrease the antihypertensive activities of Torasemide.
Olanzapine	Olanzapine Olanzapine may increase the hypotensive activities of Lurasidone.
Alosetron	Alosetron The risk or severity of adverse effects can be increased when Alosetron is combined with Lurasidone.
Dofetilide	Dofetilide The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Dofetilide.
Entacapone	Entacapone The therapeutic efficacy of Entacapone can be decreased when used in combination with Lurasidone.
Eprosartan	Eprosartan Lurasidone may decrease the antihypertensive activities of Eprosartan.
Hydroxychloroquine	Hydroxychloroquine The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Lurasidone.
Meloxicam	Meloxicam The risk or severity of hypertension can be increased when Meloxicam is combined with Lurasidone.
Oxcarbazepine	Oxcarbazepine The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Lurasidone.
Telmisartan	Telmisartan Lurasidone may decrease the antihypertensive activities of Telmisartan.
Zaleplon	Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Lurasidone.
Desloratadine	Desloratadine The risk or severity of adverse effects can be increased when Desloratadine is combined with Lurasidone.
Linezolid	Linezolid The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Lurasidone.
Trimipramine	Trimipramine Trimipramine may increase the hypotensive activities of Lurasidone.
Glycopyrrolate	Glycopyrrolate Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.
Perindopril	Perindopril Lurasidone may decrease the antihypertensive activities of Perindopril.
Choline Magnesium Trisalicylate	Choline Magnesium Trisalicylate The risk or severity of hypertension can be increased when Choline magnesium trisalicylate is combined with Lurasidone.
Dutasteride	Dutasteride The risk or severity of hypertension can be increased when Dutasteride is combined with Lurasidone.
Epinephrine Injection	Epinephrine Injection Epinephrine may increase the hypotensive activities of Lurasidone.
Eplerenone	Eplerenone Lurasidone may decrease the antihypertensive activities of Eplerenone.
Escitalopram	Escitalopram The risk or severity of serotonin syndrome can be increased when Escitalopram is combined with Lurasidone.
Olmesartan	Olmesartan Lurasidone may decrease the antihypertensive activities of Olmesartan.
Zonisamide	Zonisamide The risk or severity of adverse effects can be increased when Zonisamide is combined with Lurasidone.
Aripiprazole	Aripiprazole Aripiprazole may increase the hypotensive activities of Lurasidone.
Atomoxetine	Atomoxetine The risk or severity of adverse effects can be increased when Atomoxetine is combined with Lurasidone.
Dexmethylphenidate	Dexmethylphenidate The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Lurasidone.
Atazanavir	Atazanavir The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Lurasidone.
Almotriptan	Almotriptan The risk or severity of adverse effects can be increased when Almotriptan is combined with Lurasidone.
Eletriptan	Eletriptan The risk or severity of adverse effects can be increased when Eletriptan is combined with Lurasidone.
Mefloquine	Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Lurasidone.
Vardenafil	Vardenafil The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Lurasidone.
Alfuzosin	Alfuzosin Alfuzosin may increase the hypotensive activities of Lurasidone.
Aprepitant	Aprepitant The metabolism of Lurasidone can be decreased when combined with Aprepitant.
Memantine	Memantine The therapeutic efficacy of Memantine can be decreased when used in combination with Lurasidone.
Tegaserod	Tegaserod The risk or severity of serotonin syndrome can be increased when Tegaserod is combined with Lurasidone.
Tadalafil	Tadalafil Lurasidone may decrease the antihypertensive activities of Tadalafil.
Frovatriptan	Frovatriptan The risk or severity of adverse effects can be increased when Frovatriptan is combined with Lurasidone.
Gemifloxacin	Gemifloxacin The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Gemifloxacin.
Apomorphine Injection	Apomorphine Injection The therapeutic efficacy of Apomorphine can be decreased when used in combination with Lurasidone.
Protriptyline	Protriptyline The risk or severity of adverse effects can be increased when Protriptyline is combined with Lurasidone.
Duloxetine	Duloxetine The risk or severity of adverse effects can be increased when Lurasidone is combined with Duloxetine.
Trospium	Trospium Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Trospium.
Bosentan	Bosentan Lurasidone may decrease the antihypertensive activities of Bosentan.
Erlotinib	Erlotinib The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Erlotinib.
Eszopiclone	Eszopiclone The risk or severity of CNS depression can be increased when Lurasidone is combined with Eszopiclone.
Insulin Aspart (rDNA Origin) Injection	Insulin Aspart (rDNA Origin) Injection The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Lurasidone.
Solifenacin	Solifenacin Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.
Voriconazole	Voriconazole The metabolism of Lurasidone can be decreased when combined with Voriconazole.
Dextroamphetamine	Dextroamphetamine The therapeutic efficacy of Lurasidone can be decreased when used in combination with Amphetamine.
Pramlintide Injection	Pramlintide Injection The therapeutic efficacy of Pramlintide can be decreased when used in combination with Lurasidone.
Sodium Oxybate	Sodium Oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.
Exenatide Injection	Exenatide Injection The therapeutic efficacy of Exenatide can be decreased when used in combination with Lurasidone.
Ibandronate	Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lurasidone.
Isocarboxazid	Isocarboxazid The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Lurasidone.
Ramelteon	Ramelteon The risk or severity of adverse effects can be increased when Ramelteon is combined with Lurasidone.
Darifenacin	Darifenacin Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.
Fentanyl	Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Lurasidone.
Pregabalin	Pregabalin The therapeutic efficacy of Lurasidone can be increased when used in combination with Pregabalin.
Phenylephrine	Phenylephrine The risk or severity of hypertension can be increased when Phenylephrine is combined with Lurasidone.
Felbamate	Felbamate The risk or severity of adverse effects can be increased when Felbamate is combined with Lurasidone.
Insulin Detemir (rDNA Origin) Injection	Insulin Detemir (rDNA Origin) Injection The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Lurasidone.
Ranolazine	Ranolazine The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Ranolazine.
Rasagiline	Rasagiline The therapeutic efficacy of Rasagiline can be decreased when used in combination with Lurasidone.
Imatinib	Imatinib The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Imatinib.
Sitagliptin	Sitagliptin The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Lurasidone.
Albuterol	Albuterol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Lurasidone.
Paliperidone	Paliperidone Paliperidone may increase the hypotensive activities of Lurasidone.
Bortezomib	Bortezomib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Lurasidone.
Insulin Glulisine (rDNA origin) Injection	Insulin Glulisine (rDNA origin) Injection The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Lurasidone.
Oxaliplatin Injection	Oxaliplatin Injection The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Oxaliplatin.
Posaconazole	Posaconazole The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Lurasidone.
Primaquine	Primaquine The metabolism of Lurasidone can be decreased when combined with Primaquine.
Aliskiren	Aliskiren Lurasidone may decrease the antihypertensive activities of Aliskiren.
Bismuth Subsalicylate	Bismuth Subsalicylate Bismuth subsalicylate may increase the neurotoxic activities of Lurasidone.
Dimenhydrinate	Dimenhydrinate The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Lurasidone.
Lisdexamfetamine	Lisdexamfetamine The therapeutic efficacy of Lurasidone can be decreased when used in combination with Lisdexamfetamine.
Nabilone	Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.
Vorinostat	Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Lurasidone.
Sorafenib	Sorafenib The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Lurasidone.
Sunitinib	Sunitinib The therapeutic efficacy of Sunitinib can be decreased when used in combination with Lurasidone.
Dronabinol	Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.
Lapatinib	Lapatinib The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Lurasidone.
Levocetirizine	Levocetirizine The risk or severity of adverse effects can be increased when Levocetirizine is combined with Lurasidone.
Dasatinib	Dasatinib The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Lurasidone.
Nilotinib	Nilotinib The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Nilotinib.
Toremifene	Toremifene The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Toremifene.
Desmopressin	Desmopressin The risk or severity of hypertension can be increased when Desmopressin is combined with Lurasidone.
OnabotulinumtoxinA Injection	OnabotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lurasidone.
RimabotulinumtoxinB Injection	RimabotulinumtoxinB Injection The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Lurasidone.
Arsenic Trioxide Injection	Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Arsenic trioxide.
Desvenlafaxine	Desvenlafaxine The metabolism of Lurasidone can be decreased when combined with Desvenlafaxine.
Nebivolol	Nebivolol Lurasidone may decrease the antihypertensive activities of Nebivolol.
Flecainide	Flecainide The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Flecainide.
Rufinamide	Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Lurasidone.
Silodosin	Silodosin Silodosin may increase the hypotensive activities of Lurasidone.
Midazolam	Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Lurasidone.
Naltrexone Injection	Naltrexone Injection The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Lurasidone.
Milnacipran	Milnacipran The metabolism of Lurasidone can be decreased when combined with Milnacipran.
Fesoterodine	Fesoterodine Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.
Degarelix Injection	Degarelix Injection The risk or severity of QTc prolongation can be increased when Degarelix is combined with Lurasidone.
Betaxolol	Betaxolol The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Betaxolol.
Iloperidone	Iloperidone Iloperidone may increase the hypotensive activities of Lurasidone.
Lacosamide	Lacosamide The risk or severity of adverse effects can be increased when Lacosamide is combined with Lurasidone.
Dronedarone	Dronedarone The metabolism of Lurasidone can be decreased when combined with Dronedarone.
AbobotulinumtoxinA Injection	AbobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lurasidone.
Palonosetron Injection	Palonosetron Injection The risk or severity of adverse effects can be increased when Palonosetron is combined with Lurasidone.
Saxagliptin	Saxagliptin The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Lurasidone.
Telavancin Injection	Telavancin Injection The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Telavancin.
Romidepsin Injection	Romidepsin Injection The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Romidepsin.
Tapentadol	Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.
Pazopanib	Pazopanib The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Pazopanib.
Asenapine	Asenapine Asenapine may increase the hypotensive activities of Lurasidone.
Vigabatrin	Vigabatrin The risk or severity of adverse effects can be increased when Vigabatrin is combined with Lurasidone.
Oxymorphone	Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Lurasidone.
Liraglutide Injection	Liraglutide Injection The therapeutic efficacy of Liraglutide can be decreased when used in combination with Lurasidone.
Eribulin Injection	Eribulin Injection The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Eribulin.
IncobotulinumtoxinA Injection	IncobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lurasidone.
Vilazodone	Vilazodone The risk or severity of adverse effects can be increased when Vilazodone is combined with Lurasidone.
Terbutaline Injection	Terbutaline Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Lurasidone.
Linagliptin	Linagliptin The metabolism of Lurasidone can be decreased when combined with Linagliptin.
Rilpivirine	Rilpivirine The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Rilpivirine.
Cyclophosphamide Injection	Cyclophosphamide Injection Cyclophosphamide may increase the neurotoxic activities of Lurasidone.
Triptorelin Injection	Triptorelin Injection The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Lurasidone.
Vandetanib	Vandetanib The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Vandetanib.
Clobazam	Clobazam The risk or severity of adverse effects can be increased when Clobazam is combined with Lurasidone.
Vemurafenib	Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Lurasidone.
Crizotinib	Crizotinib The metabolism of Lurasidone can be decreased when combined with Crizotinib.
Cabergoline	Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Lurasidone.
Ambrisentan	Ambrisentan Lurasidone may decrease the antihypertensive activities of Ambrisentan.
Ezogabine	Ezogabine The risk or severity of adverse effects can be increased when Tiagabine is combined with Lurasidone.
Mirabegron	Mirabegron The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Mirabegron.
Lorcaserin	Lorcaserin The therapeutic efficacy of Mecasermin can be decreased when used in combination with Lurasidone.
Bedaquiline	Bedaquiline The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Bedaquiline.
Alogliptin	Alogliptin The therapeutic efficacy of Alogliptin can be decreased when used in combination with Lurasidone.
Pomalidomide	Pomalidomide The risk or severity of adverse effects can be increased when Lurasidone is combined with Pomalidomide.
Canagliflozin	Canagliflozin The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lurasidone.
Dabrafenib	Dabrafenib The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Dabrafenib.
Levomilnacipran	Levomilnacipran The risk or severity of adverse effects can be increased when Lurasidone is combined with Levomilnacipran.
Vortioxetine	Vortioxetine The risk or severity of adverse effects can be increased when Lurasidone is combined with Vortioxetine.
Perampanel	Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.
Ketorolac Injection	Ketorolac Injection The risk or severity of hypertension can be increased when Ketorolac is combined with Lurasidone.
Simeprevir	Simeprevir The metabolism of Lurasidone can be decreased when combined with Simeprevir.
Dapagliflozin	Dapagliflozin The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Lurasidone.
Droxidopa	Droxidopa Lurasidone may decrease the hypertensive activities of Droxidopa.
Ceritinib	Ceritinib The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Ceritinib.
Albiglutide Injection	Albiglutide Injection The therapeutic efficacy of Albiglutide can be decreased when used in combination with Lurasidone.
Eslicarbazepine	Eslicarbazepine The risk or severity of adverse effects can be increased when Lurasidone is combined with Eslicarbazepine.
Empagliflozin	Empagliflozin The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lurasidone.
Hydrocodone	Hydrocodone Hydrocodone may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.
Suvorexant	Suvorexant Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Dulaglutide Injection	Dulaglutide Injection The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Lurasidone.
Methamphetamine	Methamphetamine The therapeutic efficacy of Lurasidone can be decreased when used in combination with Metamfetamine.
Tasimelteon	Tasimelteon The risk or severity of adverse effects can be increased when Lurasidone is combined with Tasimelteon.
Riociguat	Riociguat Lurasidone may decrease the antihypertensive activities of Riociguat.
Risperidone Injection	Risperidone Injection Risperidone may increase the hypotensive activities of Lurasidone.
Insulin Human Inhalation	Insulin Human Inhalation The therapeutic efficacy of Insulin human can be decreased when used in combination with Lurasidone.
Lenvatinib	Lenvatinib The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Lenvatinib.
Panobinostat	Panobinostat The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Panobinostat.
Haloperidol Injection	Haloperidol Injection The metabolism of Lurasidone can be decreased when combined with Haloperidol.
Ivabradine	Ivabradine The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Ivabradine.
Isavuconazonium Injection	Isavuconazonium Injection The metabolism of Lurasidone can be decreased when combined with Isavuconazonium.
Macitentan	Macitentan Lurasidone may decrease the antihypertensive activities of Macitentan.
Flibanserin	Flibanserin The risk or severity of adverse effects can be increased when Flibanserin is combined with Lurasidone.
Brexpiprazole	Brexpiprazole Brexpiprazole may increase the hypotensive activities of Lurasidone.
Ziprasidone Injection	Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Lurasidone.
Cariprazine	Cariprazine The risk or severity of adverse effects can be increased when Cariprazine is combined with Lurasidone.
Eluxadoline	Eluxadoline The risk or severity of serotonin syndrome can be increased when Lurasidone is combined with Eluxadoline.
Insulin Degludec (rDNA Origin) Injection	Insulin Degludec (rDNA Origin) Injection The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Lurasidone.
Brivaracetam Injection	Brivaracetam Injection The risk or severity of adverse effects can be increased when Brivaracetam is combined with Lurasidone.
Venetoclax	Venetoclax The metabolism of Lurasidone can be decreased when combined with Venetoclax.
Midodrine	Midodrine The risk or severity of hypertension can be increased when Midodrine is combined with Lurasidone.
Selexipag	Selexipag Lurasidone may decrease the antihypertensive activities of Selexipag.
Pimavanserin	Pimavanserin The risk or severity of adverse effects can be increased when Pimavanserin is combined with Lurasidone.
Diphenhydramine Injection	Diphenhydramine Injection The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lurasidone.
Furosemide Injection	Furosemide Injection Lurasidone may decrease the antihypertensive activities of Furosemide.
Lixisenatide Injection	Lixisenatide Injection The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Lurasidone.
Ribociclib	Ribociclib The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Ribociclib.
Doxepin (Insomnia)	Doxepin (Insomnia) Doxepin may increase the hypotensive activities of Lurasidone.
Deutetrabenazine	Deutetrabenazine The risk or severity of adverse effects can be increased when Lurasidone is combined with Deutetrabenazine.
Safinamide	Safinamide The therapeutic efficacy of Safinamide can be decreased when used in combination with Lurasidone.
Delafloxacin	Delafloxacin The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Delafloxacin.
Semaglutide Injection	Semaglutide Injection The therapeutic efficacy of Semaglutide can be decreased when used in combination with Lurasidone.
Tetrabenazine	Tetrabenazine The risk or severity of adverse effects can be increased when Lurasidone is combined with Tetrabenazine.
Ertugliflozin	Ertugliflozin The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Lurasidone.
Buprenorphine Injection	Buprenorphine Injection Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Lofexidine	Lofexidine The therapeutic efficacy of Lurasidone can be increased when used in combination with Lofexidine.
Eliglustat	Eliglustat The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Eliglustat.
Encorafenib	Encorafenib The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Encorafenib.
Ivosidenib	Ivosidenib The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Ivosidenib.
Cannabidiol	Cannabidiol The risk or severity of adverse effects can be increased when Cannabidiol is combined with Lurasidone.
Stiripentol	Stiripentol The risk or severity of adverse effects can be increased when Lurasidone is combined with Stiripentol.
Gilteritinib	Gilteritinib The therapeutic efficacy of Lurasidone can be decreased when used in combination with Gilteritinib.
Glasdegib	Glasdegib The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Glasdegib.
Paclitaxel (with albumin) Injection	Paclitaxel (with albumin) Injection Paclitaxel may increase the neurotoxic activities of Lurasidone.
Siponimod	Siponimod The risk or severity of hypertension can be increased when Lurasidone is combined with Siponimod.
Brexanolone Injection	Brexanolone Injection The risk or severity of adverse effects can be increased when Lurasidone is combined with Brexanolone.
Solriamfetol	Solriamfetol The risk or severity of hypertension can be increased when Solriamfetol is combined with Lurasidone.
Triclabendazole	Triclabendazole The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Triclabendazole.
Entrectinib	Entrectinib The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Entrectinib.
Pitolisant	Pitolisant The serum concentration of Lurasidone can be decreased when it is combined with Pitolisant.
Lefamulin	Lefamulin Lefamulin may increase the QTc-prolonging activities of Lurasidone.
Phenytoin Injection	Phenytoin Injection The risk or severity of adverse effects can be increased when Phenytoin is combined with Lurasidone.
Fosphenytoin Injection	Fosphenytoin Injection The risk or severity of adverse effects can be increased when Fosphenytoin is combined with Lurasidone.
Lumateperone	Lumateperone The risk or severity of adverse effects can be increased when Lumateperone is combined with Lurasidone.
Lasmiditan	Lasmiditan The risk or severity of serotonin syndrome can be increased when Lurasidone is combined with Lasmiditan.
Cenobamate	Cenobamate The serum concentration of Lurasidone can be decreased when it is combined with Cenobamate.
Tucatinib	Tucatinib The metabolism of Tucatinib can be decreased when combined with Lurasidone.
Selpercatinib	Selpercatinib The risk or severity of hypertension can be increased when Lurasidone is combined with Selpercatinib.
Lemborexant	Lemborexant The risk or severity of adverse effects can be increased when Lurasidone is combined with Lemborexant.
Fenfluramine	Fenfluramine The risk or severity of serotonin syndrome can be increased when Fenfluramine is combined with Lurasidone.
Fostemsavir	Fostemsavir The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Fostemsavir.
Octreotide	Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lurasidone.
Opicapone	Opicapone The therapeutic efficacy of Opicapone can be decreased when used in combination with Lurasidone.
Satralizumab-mwge Injection	Satralizumab-mwge Injection The serum concentration of Lurasidone can be decreased when it is combined with Satralizumab.
Naxitamab-gqgk Injection	Naxitamab-gqgk Injection The risk or severity of hypertension can be increased when Lurasidone is combined with Naxitamab.
Relugolix	Relugolix The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Relugolix.
Viloxazine	Viloxazine The risk or severity of adverse effects can be increased when Lurasidone is combined with Viloxazine.
Fenoprofen	Fenoprofen The risk or severity of hypertension can be increased when Fenoprofen is combined with Lurasidone.
Indomethacin	Indomethacin The risk or severity of hypertension can be increased when Indomethacin is combined with Lurasidone.
Mefenamic Acid	Mefenamic Acid The risk or severity of hypertension can be increased when Mefenamic acid is combined with Lurasidone.
Naproxen	Naproxen The risk or severity of hypertension can be increased when Naproxen is combined with Lurasidone.
Tolmetin	Tolmetin The risk or severity of hypertension can be increased when Tolmetin is combined with Lurasidone.
Sulindac	Sulindac The risk or severity of hypertension can be increased when Sulindac is combined with Lurasidone.
Trazodone	Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Lurasidone.
Phenobarbital	Phenobarbital The risk or severity of adverse effects can be increased when Phenobarbital is combined with Lurasidone.
Metaxalone	Metaxalone The risk or severity of adverse effects can be increased when Metaxalone is combined with Lurasidone.
Levorphanol	Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Lurasidone.
Primidone	Primidone The risk or severity of adverse effects can be increased when Primidone is combined with Lurasidone.
Methsuximide	Methsuximide The risk or severity of adverse effects can be increased when Methsuximide is combined with Lurasidone.
Diethylpropion	Diethylpropion The therapeutic efficacy of Lurasidone can be decreased when used in combination with Diethylpropion.
Chlorpromazine	Chlorpromazine Chlorpromazine may increase the hypotensive activities of Lurasidone.
Diazepam	Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Lurasidone.
Oxazepam	Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Lurasidone.
Flurazepam	Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Lurasidone.
Clorazepate	Clorazepate The risk or severity of adverse effects can be increased when Clorazepic acid is combined with Lurasidone.
Lorazepam	Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Lurasidone.
Phenoxybenzamine	Phenoxybenzamine Phenoxybenzamine may increase the hypotensive activities of Lurasidone.
Amantadine	Amantadine The therapeutic efficacy of Amantadine can be decreased when used in combination with Lurasidone.
Codeine	Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Lurasidone.
Meprobamate	Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Lurasidone.
Chlordiazepoxide	Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lurasidone.
Bromocriptine	Bromocriptine Bromocriptine may increase the hypotensive activities of Lurasidone.
Metaproterenol	Metaproterenol The risk or severity of hypertension can be increased when Orciprenaline is combined with Lurasidone.
Tranylcypromine	Tranylcypromine The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lurasidone.
Phenelzine	Phenelzine The risk or severity of adverse effects can be increased when Phenelzine is combined with Lurasidone.
Procarbazine	Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Lurasidone.
Ergoloid Mesylates	Ergoloid Mesylates The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Lurasidone.
Minocycline	Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.
Prochlorperazine	Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lurasidone.
Thioridazine	Thioridazine Thioridazine may increase the hypotensive activities of Lurasidone.
Trifluoperazine	Trifluoperazine Trifluoperazine may increase the hypotensive activities of Lurasidone.
Sulfadiazine	Sulfadiazine The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Lurasidone.
Oxycodone	Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Lurasidone.
Methadone	Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Lurasidone.
Oxybutynin	Oxybutynin Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.
Benztropine	Benztropine The risk or severity of adverse effects can be increased when Lurasidone is combined with Benzatropine.
Maprotiline	Maprotiline The risk or severity of adverse effects can be increased when Maprotiline is combined with Lurasidone.
Ibuprofen	Ibuprofen The risk or severity of hypertension can be increased when Ibuprofen is combined with Lurasidone.
Trihexyphenidyl	Trihexyphenidyl The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Lurasidone.
Orphenadrine	Orphenadrine Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Perphenazine	Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Lurasidone.
Fluphenazine	Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Lurasidone.
Phentermine	Phentermine The therapeutic efficacy of Lurasidone can be decreased when used in combination with Phentermine.
Methylphenidate	Methylphenidate The risk or severity of adverse effects can be increased when Lurasidone is combined with Methylphenidate.
Amoxapine	Amoxapine Amoxapine may increase the hypotensive activities of Lurasidone.
Sulfasalazine	Sulfasalazine The risk or severity of hypertension can be increased when Sulfasalazine is combined with Lurasidone.
Carbamazepine	Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Lurasidone.
Molindone	Molindone The risk or severity of adverse effects can be increased when Molindone is combined with Lurasidone.
Methyldopa	Methyldopa Lurasidone may decrease the antihypertensive activities of Methyldopa.
Clonidine	Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Lurasidone.
Prazosin	Prazosin Prazosin may increase the hypotensive activities of Lurasidone.
Hydralazine	Hydralazine Lurasidone may decrease the antihypertensive activities of Hydralazine.
Warfarin	Warfarin The risk or severity of adverse effects can be increased when Lurasidone is combined with Warfarin.
Clonazepam	Clonazepam The risk or severity of adverse effects can be increased when Clonazepam is combined with Lurasidone.
Loperamide	Loperamide The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Loperamide.
Promethazine	Promethazine The risk or severity of adverse effects can be increased when Promethazine is combined with Lurasidone.
Meclofenamate	Meclofenamate The risk or severity of hypertension can be increased when Meclofenamic acid is combined with Lurasidone.
Digoxin	Digoxin The risk or severity of QTc prolongation can be increased when Digoxin is combined with Lurasidone.
Loxapine	Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Lurasidone.
Chloroquine	Chloroquine The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Chloroquine.
Quinine	Quinine The risk or severity of adverse effects can be increased when Quinine is combined with Lurasidone.
Ethosuximide	Ethosuximide The risk or severity of adverse effects can be increased when Ethosuximide is combined with Lurasidone.
Chlorothiazide	Chlorothiazide Lurasidone may decrease the antihypertensive activities of Chlorothiazide.
Chlorthalidone	Chlorthalidone Lurasidone may decrease the antihypertensive activities of Chlorthalidone.
Metolazone	Metolazone Lurasidone may decrease the antihypertensive activities of Metolazone.
Clindamycin Injection	Clindamycin Injection Clindamycin may increase the neurotoxic activities of Lurasidone.
Secobarbital	Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Lurasidone.
Desipramine	Desipramine Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
Amitriptyline	Amitriptyline Amitriptyline may increase the hypotensive activities of Lurasidone.
Imipramine	Imipramine Imipramine may increase the hypotensive activities of Lurasidone.
Quinidine	Quinidine Quinidine may increase the hypotensive activities of Lurasidone.
Procainamide	Procainamide The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Procainamide.
Isoniazid	Isoniazid The metabolism of Lurasidone can be decreased when combined with Isoniazid.
Disopyramide	Disopyramide The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Disopyramide.
Valproic Acid	Valproic Acid The risk or severity of adverse effects can be increased when Valproic acid is combined with Lurasidone.
Tamoxifen	Tamoxifen The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Lurasidone.
Butabarbital	Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Lurasidone.
Chlorpropamide	Chlorpropamide The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Lurasidone.
Tolbutamide	Tolbutamide The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Lurasidone.
Tolazamide	Tolazamide The therapeutic efficacy of Tolazamide can be decreased when used in combination with Lurasidone.
Dextromethorphan	Dextromethorphan The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Lurasidone.
Cyclobenzaprine	Cyclobenzaprine The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Lurasidone.
Baclofen	Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Lurasidone.
Doxylamine	Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.
Cyproheptadine	Cyproheptadine Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.
Clemastine	Clemastine The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Clemastine.
Chlorpheniramine	Chlorpheniramine The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Chlorpheniramine.
Brompheniramine	Brompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lurasidone.
Meclizine	Meclizine The risk or severity of adverse effects can be increased when Meclizine is combined with Lurasidone.
Hydrochlorothiazide	Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Lurasidone.
Dantrolene	Dantrolene The risk or severity of adverse effects can be increased when Dantrolene is combined with Lurasidone.
Chlorzoxazone	Chlorzoxazone The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Lurasidone.
Carisoprodol	Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Lurasidone.
Methocarbamol	Methocarbamol The risk or severity of adverse effects can be increased when Methocarbamol is combined with Lurasidone.
Danazol	Danazol The metabolism of Lurasidone can be decreased when combined with Danazol.
Disulfiram	Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Lurasidone.
Propranolol (Cardiovascular)	Propranolol (Cardiovascular) The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Propranolol.
Minoxidil	Minoxidil Lurasidone may decrease the antihypertensive activities of Minoxidil.
Pseudoephedrine	Pseudoephedrine The therapeutic efficacy of Lurasidone can be decreased when used in combination with Pseudoephedrine.
Nortriptyline	Nortriptyline Nortriptyline may increase the hypotensive activities of Lurasidone.
Nadolol	Nadolol Lurasidone may decrease the antihypertensive activities of Nadolol.
Butorphanol Injection	Butorphanol Injection The risk or severity of adverse effects can be increased when Butorphanol is combined with Lurasidone.
Nalbuphine Injection	Nalbuphine Injection The risk or severity of adverse effects can be increased when Nalbuphine is combined with Lurasidone.
Oxytocin Injection	Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lurasidone.
Trimethobenzamide	Trimethobenzamide The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Lurasidone.
Flavoxate	Flavoxate Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.
Papaverine	Papaverine The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Papaverine.
Fluorouracil Injection	Fluorouracil Injection The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Fluorouracil.
Acetazolamide	Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Lurasidone.
Ketoconazole	Ketoconazole The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Lurasidone.
Pyrantel	Pyrantel The risk or severity of adverse effects can be increased when Lurasidone is combined with Pyrantel.
Vincristine Injection	Vincristine Injection Vincristine may increase the neurotoxic activities of Lurasidone.
Captopril	Captopril Lurasidone may decrease the antihypertensive activities of Captopril.
Isoxsuprine	Isoxsuprine The risk or severity of hypertension can be increased when Lurasidone is combined with Isoxsuprine.
Metoprolol	Metoprolol Lurasidone may decrease the antihypertensive activities of Metoprolol.
Hydroxyzine	Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Lurasidone.
Thiothixene	Thiothixene The risk or severity of adverse effects can be increased when Thiothixene is combined with Lurasidone.
Aspirin	Aspirin The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Lurasidone.
Salsalate	Salsalate The risk or severity of hypertension can be increased when Salsalate is combined with Lurasidone.
Alprazolam	Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Lurasidone.
Temazepam	Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Lurasidone.
Triazolam	Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Lurasidone.
Dicyclomine	Dicyclomine Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.
Hyoscyamine	Hyoscyamine Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Propantheline	Propantheline Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Propantheline.
Diltiazem	Diltiazem The metabolism of Lurasidone can be decreased when combined with Diltiazem.
Nifedipine	Nifedipine The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Nifedipine.
Timolol	Timolol The risk or severity of QTc prolongation can be increased when Timolol is combined with Lurasidone.
Verapamil	Verapamil The metabolism of Lurasidone can be decreased when combined with Verapamil.
Atenolol	Atenolol Lurasidone may decrease the antihypertensive activities of Atenolol.
Pindolol	Pindolol The risk or severity of adverse effects can be increased when Pindolol is combined with Lurasidone.
Diflunisal	Diflunisal The risk or severity of hypertension can be increased when Diflunisal is combined with Lurasidone.
Piroxicam	Piroxicam The risk or severity of hypertension can be increased when Piroxicam is combined with Lurasidone.
Glyburide	Glyburide The therapeutic efficacy of Glyburide can be decreased when used in combination with Lurasidone.
Glipizide	Glipizide The therapeutic efficacy of Glipizide can be decreased when used in combination with Lurasidone.
Indapamide	Indapamide The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Indapamide.
Pentamidine Injection	Pentamidine Injection The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Pentamidine.
Labetalol	Labetalol Labetalol may increase the hypotensive activities of Lurasidone.
Leuprolide Injection	Leuprolide Injection The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Leuprolide.
Guanabenz	Guanabenz The risk or severity of hypertension can be increased when Guanabenz is combined with Lurasidone.
Ketoprofen	Ketoprofen The risk or severity of hypertension can be increased when Ketoprofen is combined with Lurasidone.
Pimozide	Pimozide The risk or severity of adverse effects can be increased when Pimozide is combined with Lurasidone.
Enalapril	Enalapril Lurasidone may decrease the antihypertensive activities of Enalapril.
Flurbiprofen	Flurbiprofen The risk or severity of hypertension can be increased when Flurbiprofen is combined with Lurasidone.
Amiodarone	Amiodarone The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Amiodarone.
Buspirone	Buspirone The risk or severity of serotonin syndrome can be increased when Buspirone is combined with Lurasidone.
Lovastatin	Lovastatin The metabolism of Lurasidone can be decreased when combined with Lovastatin.
Ciprofloxacin	Ciprofloxacin The metabolism of Lurasidone can be decreased when combined with Ciprofloxacin.
Mesalamine	Mesalamine The risk or severity of hypertension can be increased when Mesalazine is combined with Lurasidone.
Diclofenac	Diclofenac The risk or severity of hypertension can be increased when Diclofenac is combined with Lurasidone.
Fluoxetine	Fluoxetine The risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Lurasidone.
Nimodipine	Nimodipine The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Nimodipine.
Clozapine	Clozapine The metabolism of Lurasidone can be decreased when combined with Clozapine.
Estazolam	Estazolam The risk or severity of adverse effects can be increased when Estazolam is combined with Lurasidone.
Ofloxacin	Ofloxacin The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Ofloxacin.
Didanosine	Didanosine Didanosine may increase the neurotoxic activities of Lurasidone.
Clarithromycin	Clarithromycin The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Clarithromycin.
Benazepril	Benazepril Lurasidone may decrease the antihypertensive activities of Benazepril.
Etodolac	Etodolac The risk or severity of hypertension can be increased when Etodolac is combined with Lurasidone.
Felodipine	Felodipine The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Felodipine.
Fosinopril	Fosinopril Lurasidone may decrease the antihypertensive activities of Fosinopril.
Nabumetone	Nabumetone The risk or severity of hypertension can be increased when Nabumetone is combined with Lurasidone.
Quinapril	Quinapril Lurasidone may decrease the antihypertensive activities of Quinapril.
Ramipril	Ramipril Lurasidone may decrease the antihypertensive activities of Ramipril.
Amlodipine	Amlodipine Lurasidone may decrease the antihypertensive activities of Amlodipine.
Teniposide Injection	Teniposide Injection Teniposide may increase the neurotoxic activities of Lurasidone.
Itraconazole	Itraconazole The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Lurasidone.
Lisinopril	Lisinopril Lurasidone may decrease the antihypertensive activities of Lisinopril.
Oxaprozin	Oxaprozin The risk or severity of hypertension can be increased when Oxaprozin is combined with Lurasidone.
Sotalol	Sotalol The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Sotalol.
Bisoprolol	Bisoprolol Lurasidone may decrease the antihypertensive activities of Bisoprolol.
Zolpidem	Zolpidem Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Doxazosin	Doxazosin Doxazosin may increase the hypotensive activities of Lurasidone.
Terazosin	Terazosin Terazosin may increase the hypotensive activities of Lurasidone.
Isradipine	Isradipine The metabolism of Lurasidone can be decreased when combined with Isradipine.
Cisapride	Cisapride The risk or severity of adverse effects can be increased when Cisapride is combined with Lurasidone.
Gabapentin	Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Lurasidone.
Venlafaxine	Venlafaxine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Lurasidone.
Stavudine	Stavudine Stavudine may increase the neurotoxic activities of Lurasidone.
Fluvoxamine	Fluvoxamine The metabolism of Lurasidone can be decreased when combined with Fluvoxamine.
Nefazodone	Nefazodone Nefazodone may increase the hypotensive activities of Lurasidone.
Lamotrigine	Lamotrigine The risk or severity of adverse effects can be increased when Lamotrigine is combined with Lurasidone.
Losartan	Losartan The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Losartan.
Tramadol	Tramadol The risk or severity of serotonin syndrome can be increased when Lurasidone is combined with Tramadol.
Vinorelbine Injection	Vinorelbine Injection Vinorelbine may increase the neurotoxic activities of Lurasidone.
Moexipril	Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Lurasidone.
Nicardipine	Nicardipine The metabolism of Lurasidone can be decreased when combined with Nicardipine.
Bupropion	Bupropion The risk or severity of adverse effects can be increased when Bupropion is combined with Lurasidone.
Saquinavir	Saquinavir The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Saquinavir.
Metformin	Metformin The therapeutic efficacy of Metformin can be decreased when used in combination with Lurasidone.
Nisoldipine	Nisoldipine Lurasidone may decrease the antihypertensive activities of Nisoldipine.
Riluzole	Riluzole The risk or severity of adverse effects can be increased when Riluzole is combined with Lurasidone.
Acarbose	Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Lurasidone.
Glimepiride	Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Lurasidone.
Ritonavir	Ritonavir The serum concentration of Lurasidone can be increased when it is combined with Ritonavir.
Clomipramine	Clomipramine The risk or severity of adverse effects can be increased when Clomipramine is combined with Lurasidone.
Mirtazapine	Mirtazapine Lurasidone may increase the serotonergic activities of Mirtazapine.
Trandolapril	Trandolapril Lurasidone may decrease the antihypertensive activities of Trandolapril.
Topiramate	Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with Lurasidone.
Valsartan	Valsartan Lurasidone may decrease the antihypertensive activities of Valsartan.
Insulin Lispro Injection	Insulin Lispro Injection The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Lurasidone.
Pramipexole	Pramipexole The therapeutic efficacy of Pramipexole can be decreased when used in combination with Lurasidone.
Donepezil	Donepezil The risk or severity of adverse effects can be increased when Donepezil is combined with Lurasidone.
Nelfinavir	Nelfinavir The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Lurasidone.
Azithromycin	Azithromycin The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Azithromycin.
Carvedilol	Carvedilol Carvedilol may increase the hypotensive activities of Lurasidone.
Selegiline	Selegiline The risk or severity of adverse effects can be increased when Selegiline is combined with Lurasidone.
Sertraline	Sertraline The risk or severity of adverse effects can be increased when Lurasidone is combined with Sertraline.
Propafenone	Propafenone The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Propafenone.
Irbesartan	Irbesartan Lurasidone may decrease the antihypertensive activities of Irbesartan.
Tamsulosin	Tamsulosin Tamsulosin may increase the hypotensive activities of Lurasidone.
Ropinirole	Ropinirole The therapeutic efficacy of Ropinirole can be decreased when used in combination with Lurasidone.
Finasteride	Finasteride The risk or severity of hypertension can be increased when Finasteride is combined with Lurasidone.
Quetiapine	Quetiapine Quetiapine may increase the hypotensive activities of Lurasidone.
Cetirizine	Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Lurasidone.
Paroxetine	Paroxetine The risk or severity of adverse effects can be increased when Lurasidone is combined with Paroxetine.
Tolcapone	Tolcapone The therapeutic efficacy of Tolcapone can be decreased when used in combination with Lurasidone.
Citalopram	Citalopram The risk or severity of adverse effects can be increased when Lurasidone is combined with Citalopram.
Efavirenz	Efavirenz The risk or severity of adverse effects can be increased when Efavirenz is combined with Lurasidone.
Pioglitazone	Pioglitazone The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Lurasidone.
Celecoxib	Celecoxib The risk or severity of hypertension can be increased when Celecoxib is combined with Lurasidone.
Rosiglitazone	Rosiglitazone The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Lurasidone.
Tolterodine	Tolterodine Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.
Thalidomide	Thalidomide Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Balsalazide	Balsalazide The risk or severity of hypertension can be increased when Balsalazide is combined with Lurasidone.
Nateglinide	Nateglinide The therapeutic efficacy of Nateglinide can be decreased when used in combination with Lurasidone.
Galantamine	Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Lurasidone.
Levetiracetam	Levetiracetam The risk or severity of adverse effects can be increased when Levetiracetam is combined with Lurasidone.